PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024

Rhea-AI Summary

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology, will present at the 2024 Truist Securities MedTech Conference in Boston, Massachusetts. The presentation is scheduled for June 18, 2024, at 1:20 p.m. Eastern Time. Management will provide insights into the company's advancements and strategies. Investors can access the live webcast and archived recordings on the company's investor relations website.

Positive

• Presentation scheduled at a high-profile MedTech conference, indicating industry recognition.
• Availability of live webcast and archived recordings enhances transparency and investor engagement.
• Focus on transformative solutions in urology may attract investor interest and industry partnerships.

Negative

• No specific details on financial performance or new product announcements were provided.
• Potential for increased expenses related to conference participation not addressed.
• Uncertainty on how the presentation will impact stock performance due to lack of detailed content information.

SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics^® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time.

A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com

FAQ

What is the date of PROCEPT BioRobotics' presentation at the 2024 Truist Securities MedTech Conference?

PROCEPT BioRobotics is scheduled to present on June 18, 2024.

What time will PROCEPT BioRobotics present at the MedTech Conference?

PROCEPT BioRobotics will present at 1:20 p.m. Eastern Time.

Where will the 2024 Truist Securities MedTech Conference take place?

The conference will take place in Boston, Massachusetts.

How can I watch PROCEPT BioRobotics' presentation at the 2024 Truist Securities MedTech Conference?

You can watch the live webcast and archived recordings on the 'Investors' section of PROCEPT BioRobotics' website.

How long will the webcast be available for replay?

The webcast will be archived and available for replay for at least 90 days after the event.